Pharma used to have industry research labs but are closing them down as they realise they can save money. Get rid of their industry labs and buy-in drugs made by academics, because they are not sufficiently business savy and they can pick up a bargain.
Academics think they can save the world and invent and develop drugs. However the reality is very different. Academics are great at developing treatments but they are not so good at commercialising these ideas. In between the initial academic fumblings into the business world and industry-based drug development is the “Valley of Death” Most studies academic fail to attract sufficient investment and they die a quick of slow death in the valley.
However, there are two valley of deaths
Another Valley of death is for academic neurologists who are great at doing trials but then what. They do a phase II/phase III trial but the regulatory hurdle means that they can not afford to do the next trial without pharma support or they haven’t got the support to deliver what the regulators want and so the project flounders and fails.
Without investor Angels to help Cross the Valleys of Death many academics will fail to develop new drugs and this is why pharma is one of the only games in town when it comes to drug development, sometimes academics become academic entrapeneurs until they can get pharma interested